Abstract

The disclosure provides a method of producing syngas. The method comprises feeding a first input gas into a reactor. The first input gas comprises oxygen and the reactor comprises an oxygen carrier material, and thereby causes the oxygen carrier material to oxidise. The method further comprises feeding a second input gas into the reactor. The second input gas comprises carbon monoxide and/or a fuel, and thereby causes the oxygen carrier material to be reduced and the carbon monoxide and/or fuel to oxidise to produce a second output gas. The method further comprises purifying the second output gas to obtain a purified gas with a high concentration of carbon dioxide. Finally, the method comprises feeding a third input gas into the reactor. The third input gas comprises the purified gas and a hydrogen gas stream, and thereby causes syngas to be produced.

IPC Classes  ?

• C01B 3/12 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents by reaction of water vapour with carbon monoxide
• C01B 32/50 - Carbon dioxide
• C10G 2/00 - Production of liquid hydrocarbon mixtures of undefined composition from oxides of carbon

Abstract

The present invention relates to error prone DNA polymerases for organelle mutation, to methods of modifying a plant or pant thereof or organelle DNA of a plant, and plant products thereof. The invention further relates to a method of producing a plant having homoplastic modified organelle DNA using the error prone organellar DNA polymerase. The error prone organellar DNA polymerase allows plants with fixed homoplasmic modified organelle DNA to be produced.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention relates to a novel method for oligonucleotide synthesis, using a catalytic primer-template, e.g. a hairpin primer, to achieve multiple rounds of oligonucleotide synthesis and dissociation from the template in the same reaction, such that at the end of the reaction the amount of oligonucleotide generated is greater than the amount of template provided in the reaction. The primer contains a cleavable site and the reaction is carried out in a single mixture with a cleavage agent. The cleavable site may be an inosine and the agent an endonuclease V.

IPC Classes  ?

• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

A structure comprises multiple individually removable functionalised electrodes, each one of the multiple individually removable functionalised electrodes for use in at least one biosensor apparatus.

IPC Classes  ?

• G01N 27/327 - Biochemical electrodes
• G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The disclosure provides a method of functionalising sodium carboxy methylcellulose (Na-CMC) which is a cellulose comprising at least one unit of Formula (0), where at least one G0 group is (I) and the remaining G0 groups are H. The disclosure also provides a CMC derivative product obtainable by this method, wherein the CMC derivative product comprises at least one unit of Formula (3), wherein: L is (II), n is an integer from 0 to 450; X is selected from (III), (IV), (V), (VI), (VII), (VIII), and (IX); L1 is a bond, alkylene, -(alkylene)O—*, —O(alkylene)-*, or -(alkylene)C(O)—*; wherein the*is the attachment to the cyclooctene or benzene ring; Z is —F, —Cl, —Br, or —I; R2 is —L2-M; L2 is an alkylene, -(alkylene)C(O)—*, -(alkylene)NHC(O)—*, —(CH2CH2O)mCH2—*, —CH2(OCH2CH2)m—*, arylene, or a bond, wherein the*is the attachment to M and m is an integer between 1 to 450; and M is a biomolecular unit. The disclosure provides a method of functionalising sodium carboxy methylcellulose (Na-CMC) which is a cellulose comprising at least one unit of Formula (0), where at least one G0 group is (I) and the remaining G0 groups are H. The disclosure also provides a CMC derivative product obtainable by this method, wherein the CMC derivative product comprises at least one unit of Formula (3), wherein: L is (II), n is an integer from 0 to 450; X is selected from (III), (IV), (V), (VI), (VII), (VIII), and (IX); L1 is a bond, alkylene, -(alkylene)O—*, —O(alkylene)-*, or -(alkylene)C(O)—*; wherein the*is the attachment to the cyclooctene or benzene ring; Z is —F, —Cl, —Br, or —I; R2 is —L2-M; L2 is an alkylene, -(alkylene)C(O)—*, -(alkylene)NHC(O)—*, —(CH2CH2O)mCH2—*, —CH2(OCH2CH2)m—*, arylene, or a bond, wherein the*is the attachment to M and m is an integer between 1 to 450; and M is a biomolecular unit.

IPC Classes  ?

• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 49/00 - Preparations for testing in vivo

Abstract

A guidance system for guiding a clinician in delivering a needle to a target location within a hollow organ in a patient's body. The guidance system includes: a computing device; a target sensor configured to provide target sensor data describing the position of the target sensor, wherein the target sensor is configured to be positioned at or proximate to the target location within the hollow organ; a needle sensor configured to be carried by the needle or a device on which the needle is mounted, and to provide needle sensor data describing the position and orientation of the needle; at least one information delivery device configured to deliver information to the clinician. The computing device is configured to, using the target sensor data and needle sensor data, compute targeting information describing at least the orientation of the needle relative to the target location, and to use the at least one information delivery device to deliver guidance information to the clinician for assisting the clinician in delivering the needle to the target location, based on the targeting information

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets
• A61B 17/34 - Trocars; Puncturing needles

Abstract

Monomer as a cross-linker for polymers The present invention provides a use of a monomer as a cross-linker in ring-opening polymerisation, a cross-linked polymer which comprises the monomer and a method of preparing a cross-linked polymer.

IPC Classes  ?

• C08G 63/08 - Lactones or lactides
• C08G 63/688 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing sulfur
• C08G 63/84 - Boron, aluminium, gallium, indium, thallium, rare earth metals, or compounds thereof

Abstract

The present invention relates to compounds of formula (I) and formula (II). The compounds of the invention may be used in a method of treatment of a fungal infection, a bacterial infection, or an ameobic infection.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/52 - Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring

Abstract

This invention relates to therapeutic 6-substituted naphthalene-1,3-disulfonic acid derivatives of formula (I) (Formula (I)). More specifically, the invention relates to compounds of formula (I) useful as modulators of extracellular nicotinamide phosphoribosyl transferase (eNAMPT) that stabilize the protein in its dimeric form. In addition the invention contemplates pharmaceutical compositions comprising the compounds, processes to prepare the compounds and the compounds for use in methods of medical treatment of e.g. (i) diabetes; (ii) cardiovascular disease; (iii) inflammatory bowel condition; (iv) cancer; (v) liver disease; (vi) inflammatory skin conditions; (vii) lung conditions; (viii) arthritis; (ix) kidney disease (e.g. chronic kidney disease); or (x) sepsis. An exemplary compound is e.g. 6-(2-fluoro-5-((3-(4-(piperidin-1-ylsulfonyl) phenyl) ureido)methyl)phenyl)-4-(trioxidaneylthio) naphthalene-2-sulfonic acid (example 1). This invention relates to therapeutic 6-substituted naphthalene-1,3-disulfonic acid derivatives of formula (I) (Formula (I)). More specifically, the invention relates to compounds of formula (I) useful as modulators of extracellular nicotinamide phosphoribosyl transferase (eNAMPT) that stabilize the protein in its dimeric form. In addition the invention contemplates pharmaceutical compositions comprising the compounds, processes to prepare the compounds and the compounds for use in methods of medical treatment of e.g. (i) diabetes; (ii) cardiovascular disease; (iii) inflammatory bowel condition; (iv) cancer; (v) liver disease; (vi) inflammatory skin conditions; (vii) lung conditions; (viii) arthritis; (ix) kidney disease (e.g. chronic kidney disease); or (x) sepsis. An exemplary compound is e.g. 6-(2-fluoro-5-((3-(4-(piperidin-1-ylsulfonyl) phenyl) ureido)methyl)phenyl)-4-(trioxidaneylthio) naphthalene-2-sulfonic acid (example 1).

IPC Classes  ?

• C07D 491/08 - Bridged systems
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• C07C 317/42 - Y being a hetero atom
• C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 211/96 - Sulfur atom
• C07D 249/06 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to computer-implemented methods for predicting catalytic activity for a candidate mutant enzyme comprising estimating the electrostatic component of the activation barrier for each of a plurality of conformations of each candidate mutant enzyme, for predicting catalytic activity for a candidate mutant enzyme using a machine learning model trained using data obtained using such methods, for providing a site directed mutagenesis potential map for an enzyme using the described methods, and for identifying a candidate enzyme with improved catalytic activity using the described methods. Related systems and computer-readable media are also described.

IPC Classes  ?

• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 20/50 - Mutagenesis
• G16B 40/20 - Supervised data analysis

Abstract

The present invention relates to methods for identifying and detecting potential disease specific biomarkers from biofluids. In particular, the methods involve in vivo administration of nanoparticles to a subject in a diseased state or incubating nanoparticles in a biofluid sample taken from a subject in a diseased state and analysis of the biomolecule corona formed on said nanoparticles. In addition, the present invention also relates to methods that provide a means to distinguish between a healthy and diseased state in a subject, such as for example the presence of a tumor in a human subject.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

A cryocooled electric motor (500) comprising: a stator (510) comprising a magnetic core (510,510a), a rotor (520), an armature arrangement (550) and a cryogen source arranged to provide a cryonic fluid (544) to the armature arrangement (550), in order to cool the armature arrangement (550) below a temperature of 77 K, wherein the armature arrangement (550) comprises a plurality of Litz wires (552) and wherein the armature arrangement (550) is able to provide during operation of the motor a current density of more than 25 A/mm2.

IPC Classes  ?

• H02K 3/14 - Windings characterised by the conductor shape, form or construction, e.g. with bar conductors arranged in slots with transposed conductors, e.g. twisted conductors
• H02K 55/02 - Dynamo-electric machines having windings operating at cryogenic temperatures of the synchronous type
• H02K 5/20 - Casings or enclosures characterised by the shape, form or construction thereof with channels or ducts for flow of cooling medium

Abstract

A target is provided for calibrating and determining the spatial resolution, SNR and/or CNR associated with an X-ray computed tomography system having a rotation axis about which a beam of X-rays is rotated relative to the target to produce signals that are processable to generate an image on an imaging plane perpendicular to the rotation axis. The target comprises a radiopaque body and is configured to be locatable in the system with a centre of the body on the rotation axis. A thickness direction of the body parallel to the rotation axis such that the body extends radially from its centre in the imaging plane. The body contains a plurality of non-radiopaque columns extending longitudinally in the thickness direction of the body. The columns are arranged in first sub-groups of identically-shaped columns with the columns of each first sub-group sharing a respective predetermined transverse diameter. The first sub-groups are spaced from each other, and the columns of each first sub-group are also spaced from each other. The first sub-groups are members of one or more first sets. The first sub-groups of each first set are arranged such that within that first set the first sub-groups are at respective and different radial distances from the centre, and within that first set the predetermined transverse diameters of the first sub-groups vary with distance from the centre. An image of the target generated by the system can be used to calibrate and determine the spatial resolution, SNR and/or CNR associated with the system on the basis of the predetermined column transverse diameters.

IPC Classes  ?

• G01N 23/046 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material using tomography, e.g. computed tomography [CT]
• A61B 6/03 - Computerised tomographs
• A61B 6/58 - Testing, adjusting or calibrating thereof

Abstract

The present invention relates to novel polypeptide ligands of CXCR1 and/or CXCR2 which are derived from GCP2. The invention also concerns polynucleotides encoding the polypeptide ligands, uses of the polypeptide ligands and compositions comprising the polypeptide ligands.

IPC Classes  ?

• C07K 14/52 - Cytokines; Lymphokines; Interferons
• A61K 38/19 - Cytokines; Lymphokines; Interferons
• C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Abstract

The disclosure provides improved ADAMTS13 variants with amino acid substitutions in the linker 3 region. The disclosure also provides methods for producing and using the variants.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61P 7/02 - Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, the methods can involve treatment of a subject with a therapeutic agent that degrades hyaluronan and/or an agent that neutralizes a hyaluronan receptor, e.g., CD44, such as an anti-CD44 antibody.

IPC Classes  ?

• A61K 31/728 - Hyaluronic acid
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A gate drive circuit for a power inverter leg in a power inverter comprises a first power switch with a first reverse conduction channel and a second power switch with a second reverse conduction channel. The gate drive circuit comprises a first gate drive sub-circuit for controlling switching of the first power switch and a second gate drive sub-circuit for controlling switching of the second power switch. The gate drive circuit controls switching of the first and second power switches in a complementary manner, and based on gate drive input signals to the first and second gate drive sub-circuits, the gate drive input signals being indicative of conduction conditions of the first and second reverse conduction channels and a slope of load current in an inductive-resistive load.

IPC Classes  ?

• H02M 1/00 - APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF - Details of apparatus for conversion
• H02M 7/5387 - Conversion of dc power input into ac power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only, e.g. single switched pulse inverters in a bridge configuration
• H02M 5/458 - Conversion of ac power input into ac power output, e.g. for change of voltage, for change of frequency, for change of number of phases with intermediate conversion into dc by static converters using discharge tubes or semiconductor devices to convert the intermediate dc into ac using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only

Abstract

The present invention relates to laminate membranes for filtration of solutes. The membranes comprise graphene oxide and polyvinyl amine. The invention also relates to methods of reducing the amount of solutes in a mixture using said membranes, methods of making said membranes, and uses of said membranes.

IPC Classes  ?

• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/12 - Composite membranes; Ultra-thin membranes
• B01D 69/14 - Dynamic membranes
• B01D 71/02 - Inorganic material
• B01D 71/60 - Polyamines

Abstract

A spacecraft, for example a satellite, or a part thereof having a coating comprising a 2D material on an outer surface thereof is described. The 2D material comprises one or more elements, excluding C, N and S, in an amount of at least 50 at. %; and respective oxides of the one or more elements of the 2D material have a vapour pressure of at most 10 Pa at a temperature of 323 K.

IPC Classes  ?

• C09D 1/00 - Coating compositions, e.g. paints, varnishes or lacquers, based on inorganic substances
• C01B 19/00 - Selenium; Tellurium; Compounds thereof
• C09D 5/44 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes for electrophoretic applications
• C09D 5/08 - Anti-corrosive paints
• B64G 1/22 - Parts of, or equipment specially adapted for fitting in or to, cosmonautic vehicles
• B64G 1/52 - Protection, safety or emergency devices; Survival aids
• C25D 13/02 - Electrophoretic coating characterised by the process with inorganic material

Abstract

The present invention relates to a substrate having a surface of variable infrared emissivity, wherein at least one surface of the substrate comprises a plurality of pendent composite sheets fixed thereto. The present invention also relates to methods of varying the infrared emissivity on a surface of a substrate and its uses in dynamic thermal management, camouflage technology infrared communication and as a heat regulating protective cover.

IPC Classes  ?

• F41H 3/02 - Covers, e.g. screens, nets
• B32B 3/14 - Layered products essentially comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products essentially having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material characterised by a face layer formed of separate pieces of material
• B32B 9/04 - Layered products essentially comprising a particular substance not covered by groups comprising such substance as the main or only constituent of a layer, next to another layer of a specific substance

Abstract

A compound of formula (I-A), R11-126-206-20 aryl; R21-126-206-20 aryl; p' is 1 and q' is 5 or p' is 2 and q' is 4; p + q = 6; Y is an anion; and n is 1 or 2. The compounds of formula (I-A) may be used to catalyse reactions including arylation and alkylation at the carbon atom of a C-H group in which the C atom is sp2-hybridised.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
• C07D 213/12 - Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from unsaturated compounds
• C07D 213/24 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
• C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 239/74 - Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
• C07D 245/06 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom

Abstract

The invention relates to methods for capturing, quantifying and analyzing cell free nucleic acid (cfNA) in biofluid samples, such as blood and urine.

IPC Classes  ?

• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the polypeptides comprise iduronate-2-sulfatase (IDS) tethered to a tandem repeat of Apolipoprotein E (ApoEII) or the nucleic acids comprise an iduronate-2-sulfatase (IDS) gene sequence tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence. The invention also relates to haematopoietic stem and progenitor cells (HSPCs) transduced by such nucleic acids for use in therapies.

IPC Classes  ?

• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C07K 14/775 - Apolipopeptides
• C12N 5/16 - Animal cells
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

Provided herein is a method for transferring a material from a first substrate to a second substrate via a flexible intermediate substrate comprising a support layer and a metallic adhesion layer. The method comprises lifting the material from the first substrate with the intermediate substrate, the lifting comprising adhering the material to the metallic adhesion layer by Van der Waals adhesion between the material and the metallic adhesion layer. The method comprises depositing the material from the intermediate substrate on to the second substrate, the depositing comprising adhering the material to the second substrate by Van der Waals adhesion between the material and the second substrate. Also provided herein is a method of forming a heterostructure by removing material from one or more substrates via a flexible intermediate substrate comprising a support layer and metallic adhesion layer. A flexible substrate for performing the same is also provided.

IPC Classes  ?

• B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
• C01B 32/184 - Preparation
• C01B 32/19 - Preparation by exfoliation
• H01L 29/16 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only elements of Group IV of the Periodic System in uncombined form
• C01B 32/194 - After-treatment
• C01G 41/00 - Compounds of tungsten

Abstract

A Fourier transform spectrometer comprising an interferometer comprising a fixed mirror, a movable mirror and a detector, wherein: the mirrors are positioned parallel to each other and form an optical cavity; the movable mirror is operable to move relative the fixed mirror to change the size of the optical cavity; a first mirror of the mirrors is positioned such that light received from a sample enters the optical cavity through a back of the first mirror; the detector is positioned and operable to detect light which has exited the optical cavity through a back of the second mirror of the mirrors and output an interferogram; and the mirrors are distanced from each other such that the movable mirror is at or can move to a position where at least two paths to the detector for received light reflected within the interferometer are equal length.

IPC Classes  ?

• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light

Abstract

The invention provides an engineered hepatitis B virus core protein virus-like particle (HBc VLP), said HBc VLP comprising (i) a structural protein comprising the amino acid sequence of a VLP assembling HBc protein and the amino acid sequence of an immunoglobulin binding fragment of Staphylococcal Protein A (SpA) or Streptococcal Protein G (SpG) and (ii) a cargo molecule, said cargo molecule comprising the amino acid sequence of an SpA and/or SpG binding fragment of an immunoglobulin, wherein the SpA or SpG amino acid sequence of the structural protein is bound to the immunoglobulin fragment of the cargo molecule. Methods for the production of the engineered HBc VLP, and kits, pharmaceutical compositions and vaccine compositions comprising the engineered HBc VLP are provided. Therapeutic methods involving the same are further provided.

IPC Classes  ?

• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 39/44 - Antibodies bound to carriers
• C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus
• C07K 14/31 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 7/04 - Inactivation or attenuation; Producing viral sub-units
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein is a membrane for use in membrane distillation, comprising a porous polymer matrix and functionalized graphene or graphene oxide, the graphene or graphene oxide being functionalized with a polyhedral oligomeric silsesquioxane. The present membrane have improved separation performance.

IPC Classes  ?

• B01D 69/14 - Dynamic membranes
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 71/34 - Polyvinylidene fluoride
• B01D 71/82 - Macromolecular material not specifically provided for in a single one of groups characterised by the presence of specified groups, e.g. introduced by chemical after-treatment
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

Abstract

The present invention relates to polymer compounds that have antiviral activity. The compounds have the structural Formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to compositions comprising them, and to their use in the prevention or treatment of viral infections.

IPC Classes  ?

• A61K 31/795 - Polymers containing sulfur
• A01N 31/08 - Oxygen or sulfur directly attached to an aromatic ring system
• A01P 1/00 - Disinfectants; Antimicrobial compounds or mixtures thereof
• A61P 31/12 - Antivirals
• C08F 120/38 - Esters containing sulfur
• C08F 112/14 - Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing hetero atoms

Abstract

AKR1BAKBAXBAX.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention relates to methods for simultaneously identifying and/or detecting distinct classes of biomarker in biofluid samples, such as blood.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol

Abstract

An apparatus 1 for the separation or combination of fluids comprising an outer conduit 2, at least one inner conduit 3 disposed within the outer conduit 2 and a plurality of hollow fibre membranes 4 disposed within the at least one inner conduit 3. A first fluid passageway 9 is provided between the outer conduit 2 and the at least one inner conduit 3. At least one second fluid passageway 10 is provided between the at least one inner conduit 3 and the plurality of hollow fibre membranes 4. A plurality of third fluid passageways 11 are provided within the plurality of hollow fibre membranes 4. Each of the plurality of the hollow fibre membranes 4 comprises a hydrophobic material through which vapour and/or gas is passable such that, during use, a vaporous permeate is separable from or a gas is combinable with a fluid that is within one of the at least one second fluid passageway 10 and the plurality of third fluid passageways 11.

IPC Classes  ?

• B01D 61/36 - Pervaporation; Membrane distillation; Liquid permeation
• B01D 63/04 - Hollow fibre modules comprising multiple hollow fibre assemblies

Abstract

A method 30 and an apparatus 31 for mineral extraction. The method 30 comprising providing a solution comprising 40 a plurality of solutes and selectively extracting a mineral from the solution 60 by adsorption to provide a mineral-rich solution. The method further comprises distilling the mineral-rich solution by membrane distillation 80 to increase the concentration of the mineral in the mineral-rich solution and subsequently removing the mineral from the mineral-rich solution 90.

IPC Classes  ?

• B01D 61/36 - Pervaporation; Membrane distillation; Liquid permeation
• B01D 63/04 - Hollow fibre modules comprising multiple hollow fibre assemblies

Abstract

A method 30 and apparatus 31 for performing a primary and a secondary process using thermal energy of a body of water comprising a dissolved mineral. The method 30 comprising providing 40 high temperature water 34 from the body of water 33 and low temperature water 35 at from the body of water 33 to a primary apparatus 41, wherein the high temperature water 34 is at a first temperature which is higher than a second temperature of the low temperature water 35. Performing a primary process 50 in the primary apparatus 41, wherein the primary process comprises distilling the high temperature water 34 by membrane distillation to extract freshwater vapour from the high temperature water 34, wherein either the temperature difference between the high 34 and low 35 temperature water provides a temperature gradient to drive the membrane distillation or the low temperature water 35 is used to condense freshwater vapour. Removing the low temperature water 35 from the primary apparatus 60 and performing a secondary process 70 using the low temperature water 35.

IPC Classes  ?

• B01D 61/36 - Pervaporation; Membrane distillation; Liquid permeation
• B01D 63/04 - Hollow fibre modules comprising multiple hollow fibre assemblies

Abstract

This invention relates to devices that can controllably vary the properties of graphene with respect to different wavelengths of electromagnetic radiation and particularly its optical properties. The electronically variable optical surfaces of the invention comprise graphene layers with intercalated metal (e.g. lithium) ions. The cell comprises an Li-NMC anode as ion source, an ionic liquid electrolyte, and an multilayer graphene cathode.

IPC Classes  ?

• G02F 1/1524 - Transition metal compounds
• G02B 5/00 - Optical elements other than lenses
• G02F 1/1523 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising inorganic material

Abstract

A method and system is provided for increasing lipids, biomass, and metabolite yields of a microalgae culture of cells and other organisms with conserved metabolic pathways compared to an untreated culture or organism when maintained under normal conditions. The method includes irradiating with electromagnetic ionizing radiation to induce rapid and reproducible hormetic metabolic activation in the organism cells. In an embodiment, the irradiation can be applied in a exponential or stationary phase of microalgae growth. The hormetic effect involves up-regulation of expression of lipid metabolism genes encoding enzymes that are involved in the biosynthesis of lipids with accumulation of energy reserves in the form of lipids and/or accumulation of other metabolites. The method can be implemented in a system that can interface with existing microalgae cultivation platforms, standard microalgae cultivation conditions, alongside standard microalgae culture types, and similarly with organisms with conserved metabolic pathways in their growth substrates.

IPC Classes  ?

• C12N 1/12 - Unicellular algae; Culture media therefor
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

A method and system is provided for increasing lipids, biomass, and metabolite yields of a microalgae culture of cells and other organisms with conserved metabolic pathways compared to an untreated culture or organism when maintained under normal conditions. The method includes irradiating with electromagnetic ionizing radiation to induce rapid and reproducible hormetic metabolic activation in the organism cells. In an embodiment, the irradiation can be applied in a exponential or stationary phase of microalgae growth. The hormetic effect involves up-regulation of expression of lipid metabolism genes encoding enzymes that are involved in the biosynthesis of lipids with accumulation of energy reserves in the form of lipids and/or accumulation of other metabolites. The method can be implemented in a system that can interface with existing microalgae cultivation platforms, standard microalgae cultivation conditions, alongside standard microalgae culture types, and similarly with organisms with conserved metabolic pathways in their growth substrates.

IPC Classes  ?

• C12N 1/12 - Unicellular algae; Culture media therefor
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• C12P 7/64 - Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats

Abstract

A method and system is provided for increasing lipids, biomass, and metabolite yields of a microalgae culture of cells and other organisms with conserved metabolic pathways compared to an untreated culture or organism when maintained under normal conditions. The method includes irradiating with electromagnetic ionizing radiation to induce rapid and reproducible hormetic metabolic activation in the organism cells. In an embodiment, the irradiation can be applied in a exponential or stationary phase of microalgae growth. The hormetic effect involves up-regulation of expression of lipid metabolism genes encoding enzymes that are involved in the biosynthesis of lipids with accumulation of energy reserves in the form of lipids and/or accumulation of other metabolites. The method can be implemented in a system that can interface with existing microalgae cultivation platforms, standard microalgae cultivation conditions, alongside standard microalgae culture types, and similarly with organisms with conserved metabolic pathways in their growth substrates.

IPC Classes  ?

• C12N 1/12 - Unicellular algae; Culture media therefor
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• C12P 7/64 - Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats

Abstract

An illumination insert for an NMR spectrometer, the illumination insert being shaped to receive a sample and comprising a light guide portion for guiding light from a light source, and a diffuser portion for diffusing light received from the light guide portion towards a sample received in the illumination insert.

IPC Classes  ?

• G01R 33/30 - Sample handling arrangements, e.g. sample cells, spinning mechanisms
• G01R 33/46 - NMR spectroscopy

Abstract

The present invention relates to methods of decontaminating irradiated nuclear graphite. The method comprises immersing the irradiated nuclear graphite in a molten salt electrolyte, and subjecting the irradiated nuclear graphite to an electrochemical treatment.

IPC Classes  ?

• G21F 9/00 - Treating radioactively contaminated material; Decontamination arrangements therefor
• G21F 9/30 - Processing

Abstract

The present invention provides an apparatus for preparing a composite, the apparatus comprising: a first container containing a resin; a second container containing a hardener, wherein at least one of the first or second container contains nanoparticles; a metering unit arranged to receive the resin from the first container and the hardener from the second container and configured to output a treating mixture, wherein the metering unit controls a ratio of the resin and the hardener in the treating mixture; and a treatment device arranged to receive a filament and the treating mixture, and treat the filament with the treating mixture to produce the composite.

IPC Classes  ?

• B29C 70/38 - Automated lay-up, e.g. using robots, laying filaments according to predetermined patterns
• B29B 7/32 - Mixing; Kneading continuous, with mechanical mixing or kneading devices with non-movable mixing or kneading devices
• B29B 7/90 - Fillers or reinforcements
• B29B 15/12 - Coating or impregnating of reinforcements of indefinite length
• C08J 5/24 - Impregnating materials with prepolymers which can be polymerised in situ, e.g. manufacture of prepregs
• B29C 70/32 - Shaping by lay-up, i.e. applying fibres, tape or broadsheet on a mould, former or core; Shaping by spray-up, i.e. spraying of fibres on a mould, former or core on a rotating mould, former or core
• B29C 64/314 - Preparation
• D01F 8/04 - Conjugated, i.e. bi- or multicomponent, man-made filaments or the like; Manufacture thereof from synthetic polymers
• B29C 70/52 - Pultrusion, i.e. forming and compressing by continuously pulling through a die

Abstract

The present disclosure provides compositions comprising an opsin polypeptide and an arrestin polypeptide and their use thereof. Exemplary embodiments provide a composition including an opsin polypeptide, or an opsin polypeptide and an arrestin polypeptide, wherein at least one of the opsin or arrestin polypeptide comprises at least one mutation that increases a temporal resolution of the opsin polypeptide’s response to light. The opsin polypeptide and the arrestin polypeptide can be operably linked or separate. Additionally, use of said compositions for restoring retinal photosensitivity or treating a retinal degenerative condition is also provided.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to error prone DNA polymerases for organelle mutation, to methods of modifying a plant or part thereof or organelle DNA of a plant, and plant products thereof. The invention further relates to a method of producing a plant having homoplastic modified organelle DNA using the error prone organellar DNA polymerase. The error prone organellar DNA polymerase allows plants with fixed homoplasmic modified organelle DNA to be produced.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention relates to error prone DNA polymerases for organelle mutation, to methods of modifying a plant or part thereof or organelle DNA of a plant, and plant products thereof. The invention further relates to a method of producing a plant having homoplastic modified organelle DNA using the error prone organellar DNA polymerase. The error prone organellar DNA polymerase allows plants with fixed homoplasmic modified organelle DNA to be produced.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention relates to error prone DNA polymerases for organelle mutation, to methods of modifying a plant or part thereof or organelle DNA of a plant, and plant products thereof. The invention further relates to a method of producing a plant having homoplastic modified organelle DNA using the error prone organellar DNA polymerase. The error prone organellar DNA polymerase allows plants with fixed homoplasmic modified organelle DNA to be produced.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

A computer memory apparatus is provided having a plurality of storage locations and a plurality of address decoder elements, each having a one or more input address connections for mapping to a respective one or more data elements of an input data entity. Decoding by a given one of the plurality of address decoder elements serves to conditionally activate the address decoder element depending on a function of values of the one or more data elements of the input data entity mapped to the one or more input address connection(s) and further depending on an activation threshold. Memory access operations to one of the plurality of storage locations are controlled by two or more distinct ones of the plurality of address decoder elements depending on coincidences in activation of the two or more distinct address decoder elements as a result of the decoding. A method and machine-readable instructions are also provided.

IPC Classes  ?

• G11C 11/54 - Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using elements simulating biological cells, e.g. neuron
• G06N 3/00 - Computing arrangements based on biological models

Abstract

The present invention relates to a novel method for oligonucleotide synthesis, using a catalytic primer-template, e.g. a hairpin primer, to achieve multiple rounds of oligonucleotide synthesis and dissociation from the template in the same reaction, such that at the end of the reaction the amount of oligonucleotide generated is greater than the amount of template provided in the reaction. The primer contains a cleavable site and the reaction is carried out in a single mixture with a cleavage agent. The cleavable site may be an inosine and the agent an endonuclease V.

IPC Classes  ?

• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

The present invention relates to methods for detecting the presence or absence of Parkinson's disease (PD).

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol
• G01N 27/623 - Ion mobility spectrometry combined with mass spectrometry
• G01N 30/72 - Mass spectrometers

Abstract

The present invention relates to methods for identifying high molecular mass lipids in samples. Such high molecular mass lipids may be useful as biomarkers for the identification of disease.

IPC Classes  ?

• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol

Abstract

The present invention relates to 2D-material based composite materials such as aerogels and particularly, although not exclusively, to deposition of nanoparticles on 2D-material based aerogels. Also described are methods for manufacturing such materials.

IPC Classes  ?

• C25B 11/065 - Carbon
• C01B 32/198 - Graphene oxide
• C01B 32/19 - Preparation by exfoliation
• C01B 32/194 - After-treatment
• H01M 4/92 - Metals of platinum group
• C25B 11/031 - Porous electrodes
• C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
• C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
• C25D 9/04 - Electrolytic coating other than with metals with inorganic materials
• C25D 5/18 - Electroplating using modulated, pulsed or reversing current

Abstract

The disclosure provides a method of functionalising sodium carboxymethylcellulose (Na-CMC) which is a cellulose comprising at least one unit of Formula (0), where at least one G0group is (I) and the remaining G0groups are H. The disclosure also provides a CMC derivative product obtainable by this method, wherein the CMC derivative product comprises at least one unit of Formula (3), wherein: L is (II), n is an integer from 0 to 450; X is selected from (III), (IV), (V), (VI), (VII), (VIII), and (IX); L1is a bond, alkylene, -(alkylene)O-*, -O(alkylene)-*, or -(alkylene)C(O)-*; wherein the * is the attachment to the cyclooctene or benzene ring; Z is -F, -Cl, -Br, or -I; R2is -L2-M; L222m2222mm-*, arylene, or a bond, wherein the * is the attachment to M and m is an integer between 1 to 450; and M is a biomolecular unit.

IPC Classes  ?

• C08B 11/12 - Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

This invention relates to therapeutic 6-substituted naphthalene-1,3- disulfonic acid derivatives of formula (I) (Formula (I)). More specifically, the invention relates to compounds of formula (I) useful as modulators of extracellular nicotinamide phosphoribosyl transferase (eNAMPT) that stabilize the protein in its dimeric form. In addition the invention contemplates pharmaceutical compositions comprising the compounds, processes to prepare the compounds and the compounds for use in methods of medical treatment of e.g. (i) diabetes; (ii) cardiovascular disease; (iii) inflammatory bowel condition; (iv) cancer; (v) liver disease; (vi) inflammatory skin conditions; (vii) lung conditions; (viii) arthritis; (ix) kidney disease (e.g. chronic kidney disease); or (x) sepsis. An exemplary compound is e.g. e.g. 6-(2-fluoro-5-((3-(4-(piperidin-1- ylsulfonyI) phenyl) ureido)methyl)phenyl)-4-(trioxidaneylthio) naphthalene-2-sulfonic acid (example 1).

IPC Classes  ?

• C07D 295/22 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
• C07D 295/10 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms
• C07D 249/06 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 491/08 - Bridged systems
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07C 275/28 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

This invention relates to therapeutic 6-substituted naphthalene-1,3- disulfonic acid derivatives of formula (I) (Formula (I)). More specifically, the invention relates to compounds of formula (I) useful as modulators of extracellular nicotinamide phosphoribosyl transferase (eNAMPT) that stabilize the protein in its dimeric form. In addition the invention contemplates pharmaceutical compositions comprising the compounds, processes to prepare the compounds and the compounds for use in methods of medical treatment of e.g. (i) diabetes; (ii) cardiovascular disease; (iii) inflammatory bowel condition; (iv) cancer; (v) liver disease; (vi) inflammatory skin conditions; (vii) lung conditions; (viii) arthritis; (ix) kidney disease (e.g. chronic kidney disease); or (x) sepsis. An exemplary compound is e.g. e.g. 6-(2-fluoro-5-((3-(4-(piperidin-1- ylsulfonyI) phenyl) ureido)methyl)phenyl)-4-(trioxidaneylthio) naphthalene-2-sulfonic acid (example 1).

IPC Classes  ?

• C07D 295/22 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
• A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C07C 275/28 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
• C07D 249/06 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 295/10 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 491/08 - Bridged systems

Abstract

There is provided a spatial modulator (100) for terahertz (THz) radiation. The spatial modulator (100) comprises a two-dimensional array of THz modulator pixels (200) having a layered structure. The layered structure of the two-dimensional array comprises an active matrix array (140) disposed on a back substrate layer (150) defining a two- dimensional array of back electrodes (321) of the THz modulator pixels; an electrolyte layer (130); a graphene top electrode (120), and a polymer outer layer (110) disposed on the graphene top electrode (120), wherein the polymer outer layer (110) is substantially transparent to THz radiation. The spatial modulator (100) further comprises control circuitry (400) configured to independently actively address the active matrix array (140) to control an applied voltage across each THz modulator pixel (200) to independently modulate one or more properties of each pixel in the THz region.

IPC Classes  ?

• G02F 1/292 -

Abstract

A guidance system for guiding a clinician in delivering a needle to a target location within a hollow organ in a patient's body. The guidance system includes: a computing device; a target sensor configured to provide target sensor data describing the position of the target sensor, wherein the target sensor is configured to be positioned at or proximate to the target location within the hollow organ; a needle sensor configured to be carried by the needle or a device on which the needle is mounted, and to provide needle sensor data describing the position and orientation of the needle; at least one information delivery device configured to deliver information to the clinician. The computing device is configured to, using the target sensor data and needle sensor data, compute targeting information describing at least the orientation of the needle relative to the target location, and to use the at least one information delivery device to deliver guidance information to the clinician for assisting the clinician in delivering the needle to the target location, based on the targeting information

IPC Classes  ?

• A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis

Abstract

This invention relates to devices integrally comprising fibres that have emissivities, particularly of infrared radiation, that can be controllably varied. The active emissive surface comprises graphene layers with intercalated ions.

IPC Classes  ?

• B32B 15/18 - Layered products essentially comprising metal comprising iron or steel
• B32B 7/14 - Interconnection of layers using interposed adhesives or interposed materials with bonding properties applied in spaced arrangements, e.g. in stripes
• B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
• B32B 9/04 - Layered products essentially comprising a particular substance not covered by groups comprising such substance as the main or only constituent of a layer, next to another layer of a specific substance
• B32B 15/02 - Layered products essentially comprising metal in a form other than a sheet, e.g. wire, particles
• B32B 15/14 - Layered products essentially comprising metal next to a fibrous or filamentary layer
• B32B 27/16 - Layered products essentially comprising synthetic resin specially treated, e.g. irradiated
• B32B 27/32 - Layered products essentially comprising synthetic resin comprising polyolefins

Abstract

A guidance system for guiding a clinician in delivering a needle to a target location within a hollow organ in a patient's body. The guidance system includes: a computing device; a target sensor configured to provide target sensor data describing the position of the target sensor, wherein the target sensor is configured to be positioned at or proximate to the target location within the hollow organ; a needle sensor configured to be carried by the needle or a device on which the needle is mounted, and to provide needle sensor data describing the position and orientation of the needle; at least one information delivery device configured to deliver information to the clinician. The computing device is configured to, using the target sensor data and needle sensor data, compute targeting information describing at least the orientation of the needle relative to the target location, and to use the at least one information delivery device to deliver guidance information to the clinician for assisting the clinician in delivering the needle to the target location, based on the targeting information

IPC Classes  ?

• A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 17/34 - Trocars; Puncturing needles

Abstract

Monomer as a cross-linker for polymers The present invention provides a use of a monomer as a cross-linker in ring-opening polymerisation, a cross-linked polymer which comprises the monomer and a method of preparing a cross-linked polymer.

IPC Classes  ?

• C08G 63/06 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxy carboxylic acids
• C08G 63/08 - Lactones or lactides
• C08G 63/685 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing nitrogen
• C08G 63/688 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing sulfur

Abstract

The present invention relates to compounds of formula (I) and formula (II). The compounds of the invention may be used in a method of treatment of a fungal infection, a bacterial infection, or an ameobic infection.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics
• A61P 33/04 - Amoebicides

Goods & Services

Downloadable publications in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; recorded tapes, discs, cassettes, cinematographic film in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; cd-roms in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; computer software in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; computer programs in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; sound recordings and audio-visual recordings in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; digital and pre-recorded video-tapes, cassettes, compact discs and phonograph records in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; electronic publications in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; electronic teaching publications in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; information stored on electronic, magnetic and/or by optical means in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; teaching instructional and educational apparatus and instruments in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth. Printed publications in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; books in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; periodicals in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; magazines in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; newsletters and reports in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; instructional and teaching material in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; brochures in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; information booklets in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; informational sheets in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; leaflets in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed educational materials in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; training manuals in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth. Fundraising services in relation to miscarriage, still birth, pregnancy, and pregnancy following miscarriage or still birth; charitable fundraising services for parents and families suffering a miscarriage or still birth, during pregnancy, and pregnancy following a miscarriage or still birth; providing fundraising activities to support medical research and procedures for parents and families suffering a miscarriage or still birth, during pregnancy, and pregnancy following a miscarriage or still birth; providing fundraising activities to support medical research and procedures for the prevention of miscarriages and still births; information, advisory and consultancy services in relation to all of the aforesaid. Educational services in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational instruction in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational seminars in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational consultancy in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational research in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; developing educational manuals in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational information services in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational consultancy services in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational advisory services in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; workshops for educational purposes in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; computer based educational services in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; provision of educational information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; development of educational materials in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; arranging of educational events in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; organisation of educational events in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; arranging and conducting of educational seminars in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational services in the healthcare sector in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; provision of educational services relating to health in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; publication and distribution of printed media and recordings in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; non-downloadable publications in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; advisory, consultancy and information services relating to all the aforesaid. Medical research services in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; scientific and technological services and research and design relating thereto in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; research and development and scientific and technological services and research in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; advisory, consultancy and information services relating to all the aforesaid. Midwifery services; midwifery services in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; medical services in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; health consultancy in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; counselling services in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; health counselling in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; information relating to health in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; mental health services in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; professional consultancy relating to health care in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; providing health care by telephone in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; providing health information in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; advisory, consultancy and information services relating to all the aforesaid.

Abstract

The present invention relates to computer-implemented methods for predicting catalytic activity for a candidate mutant enzyme comprising estimating the electrostatic component of the activation barrier for each of a plurality of conformations of each candidate mutant enzyme, for predicting catalytic activity for a candidate mutant enzyme using a machine learning model trained using data obtained using such methods, for providing a site directed mutagenesis potential map for an enzyme using the described methods, and for identifying a candidate enzyme with improved catalytic activity using the described methods. Related systems and computer-readable media are also described.

IPC Classes  ?

• G16B 15/20 - Protein or domain folding
• G16B 20/50 - Mutagenesis
• G16B 40/20 - Supervised data analysis

Abstract

A semiconductor structure comprising a matrix having a first cubic Group-III nitride with a first band gap, and a second cubic Group-III nitride having a second band gap and forming a region embedded within the matrix. The second cubic Group-III nitride comprises an alloying material which reduces the second band gap relative to the first band gap, a quantum wire is defined by a portion within the region embedded within the matrix, the portion forming a one-dimensional charge-carrier confinement channel, wherein the quantum wire is operable to exhibit emission luminescence which is optically polarised.

IPC Classes  ?

• H01S 5/34 - Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
• H01S 5/343 - Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser
• H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
• H01L 33/18 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular crystal structure or orientation, e.g. polycrystalline, amorphous or porous within the light emitting region
• H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof

Abstract

The present invention relates to the method of estimating or quantifying the content of recycled plastic in a plastic product using fluorescent compounds, and related methods and products.

IPC Classes  ?

• B29B 17/00 - Recovery of plastics or other constituents of waste material containing plastics
• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 33/44 - Resins; Plastics; Rubber; Leather
• C08J 3/20 - Compounding polymers with additives, e.g. colouring

Abstract

The present invention relates to the treatment of dry eye disease and particularly, although not exclusively, to the treatment of dry eye disease with a LINK_TSG6 polypeptide.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 27/04 - Artificial tears; Irrigation solutions
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 38/13 - Cyclosporins
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

A target is provided for calibrating and determining the spatial resolution, SNR and/or CNR associated with an X-ray computed tomography system having a rotation axis about which a beam of X-rays is rotated relative to the target to produce signals that are processable to generate an image on an imaging plane perpendicular to the rotation axis. The target comprises a radiopaque body and is configured to be locatable in the system with a centre of the body on the rotation axis. A thickness direction of the body parallel to the rotation axis such that the body extends radially from its centre in the imaging plane. The body contains a plurality of non-radiopaque columns extending longitudinally in the thickness direction of the body. The columns are arranged in first sub-groups of identically-shaped columns with the columns of each first sub-group sharing a respective predetermined transverse diameter. The first sub-groups are spaced from each other, and the columns of each first sub-group are also spaced from each other. The first sub-groups are members of one or more first sets. The first sub-groups of each first set are arranged such that within that first set the first sub-groups are at respective and different radial distances from the centre, and within that first set the predetermined transverse diameters of the first sub-groups vary with distance from the centre. An image of the target generated by the system can be used to calibrate and determine the spatial resolution, SNR and/or CNR associated with the system on the basis of the predetermined column transverse diameters.

IPC Classes  ?

• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment

Abstract

The present invention relates to a macromolecule scaffold comprising wood-derived cellulose. The cellulose comprises a plurality of elongate lumen and the scaffold is substantially de-lignified. The present invention also provides a method of producing a macromolecule scaffold. The method comprises treating wood with a solution comprising sodium hydroxide and sodium sulphite and a solution comprising hydrogen peroxide.

IPC Classes  ?

• C12N 11/12 - Cellulose or derivatives thereof
• C08B 1/00 - Preparatory treatment of cellulose for making derivatives thereof
• D21C 5/00 - Other processes for obtaining cellulose, e.g. cooking cotton linters
• C12N 9/10 - Transferases (2.)
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase

Goods & Services

Electronic downloadable publications, namely, newsletters, magazines and books featuring information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; pre-recorded audio and video tapes, pre-recorded audio and video discs, pre-recorded audio and video cassettes, cinematographic film featuring information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; pre-recorded CD-ROMs featuring information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; downloadable, computer software for providing information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; downloadable computer programs for providing information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; sound recordings and audio-visual recordings featuring information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; digital and pre-recorded video-tapes, cassettes, compact discs and phonograph records featuring information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth;; electronic downloadable teaching publications, namely, workbooks, books, hand-outs and fact sheets featuring information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; information stored on electronic, magnetic and by optical means, namely, downloadable computer programs for providing information, CDs and DVDs featuring information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; teaching, instructional, and educational apparatus and instruments, namely, anatomical models for teaching in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth. Printed publications, namely, namely, newsletters, magazines and books in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed books in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed periodicals in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed magazines in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed newsletters and reports in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed instructional and teaching material in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed brochures in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed information booklets in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed informational sheets in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed leaflets in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed educational materials in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; printed training manuals in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth. Charitable fundraising services to raise funds for support for parents and lifesaving research in relation to miscarriage, still birth, pregnancy, and pregnancy following miscarriage or still birth; charitable fundraising services for parents and families suffering a miscarriage or still birth, during pregnancy, and pregnancy following a miscarriage or still birth; charitable foundation services, namely, providing fundraising activities to support medical research and procedures for parents and families suffering a miscarriage or still birth, during · pregnancy, and pregnancy following a miscarriage or still birth; charitable foundation services, namely, providing fundraising activities to support medical research and procedures for the prevention of miscarriages and still births; providing information, advisory and consultancy services in relation to all of the aforesaid. Educational services, namely, conducting classes, seminars, conferences, workshops in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational instruction, namely, conducting classes, seminars, conferences, workshops in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational services, namely, conducting seminars in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational consultancy in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; providing information in relation to education in the fields of midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; research in the field of education in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; developing educational manuals for others in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational information services, namely, providing information in relation to education in the fields of midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational consultancy services in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational advisory services in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; workshops for educational purposes in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; computer based educational services, namely, conducting online classes, seminars, conferences, workshops in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; provision of educational information, namely, providing information in relation to education in the fields of midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; development and dissemination of printed educational materials in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; arranging of educational events in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; organisation of educational events in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; arranging and conducting of educational seminars in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; educational services, namely, conducting classes, seminars, conferences, workshops in the healthcare sector in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; provision of educational services, namely, conducting classes, seminars, conferences, workshops relating to health in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; publication and distribution of printed media and audio, and video recordings of others in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; providing online non-downloadable publications in the nature of newsletters, magazines and books featuring information in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; providing advisory, consultancy and information services relating to all the aforesaid. Medical research services in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; scientific and technological services, namely scientific research, analysis, testing and research and design relating thereto in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; scientific research and development and scientific and technological services, namely, scientific research, analysis, testing and medical research in relation to midwifery, miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; providing advisory, consultancy and information services relating to all the aforesaid Midwifery services; midwifery services in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; medical services in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; health care consultancy in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; health counselling services in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; health counselling in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; providing information relating to health in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; mental health services in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; professional consultancy relating to health care in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; providing health care information by telephone in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; providing health information in relation to miscarriage, still birth, pregnancy, pregnancy following miscarriage and still birth; providing advisory, consultancy and information services relating to all the aforesaid.

Abstract

The disclosure provides improved ADAMTS13 variants with amino acid substitutions in the linker 3 region. The disclosure also provides methods for producing and using the variants.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 7/02 - Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

The invention relates to molecular biomarkers and particular methods for assessing the likelihood of developing Alzheimer's disease, determining Alzheimer's disease and/or monitoring the progression of Alzheimer's disease in a subject.

IPC Classes  ?

• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The disclosure provides improved ADAMTS13 variants with amino acid substitutions in the linker 3 region. The disclosure also provides methods for producing and using the variants.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 7/02 - Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a method of increasing the number of α2,3,-α2,6-disialylgalactose N-glycans on a glycoprotein by incubating an α2,3-sialylated glycoprotein with an α2,6-sialyltransferase and a sialic acid source. Also provided is a recombinant glycoprotein comprising at least one α2,3,-α2,6-disialylgalactose N-glycan. In a particular embodiment, the recombinant glycoprotein is alpha-1 antitrypsin (AAT).

IPC Classes  ?

• C12P 21/00 - Preparation of peptides or proteins
• C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides

Abstract

A visual field assessment system (100) comprises a display device (116) having a display area; a user input device (118), and a processor (102, 104). The processor is configured to intermittently display a first visual stimulus (306) in a central display region (301 A) of the display area and intermittently display a second visual stimulus (308) in a peripheral display region (301 B) of the display area. The processor determines whether the user has correctly visually detected the second visual stimulus based on use of the user input device, and selectively displays a graphical object (310) moving from the peripheral display region towards the central display region based on the determination.

IPC Classes  ?

• A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06T 13/00 - Animation
• G06F 3/14 - Digital output to display device
• G06T 11/00 - 2D [Two Dimensional] image generation
• A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
• A63F 13/537 - Controlling the output signals based on the game progress involving additional visual information provided to the game scene, e.g. by overlay to simulate a head-up display [HUD] or displaying a laser sight in a shooting game using indicators, e.g. showing the condition of a game character on screen

Abstract

The present invention relates to methods for assessing the pluripotent state of a stem cell culture by determining the presence of marker proteins, related kits and uses.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

This invention relates to the treatment of osteoarthritic pain, or pain associated with osteoarthritis, and particularly for LINK_TSG6 polypeptide for use in the treatment of osteoarthritic pain. Osteoarthritis is caused by the deterioration of cartilage in joints and is characterised by pain and a loss of mobility in the affected joints. Osteoarthritic pain results from multiple factors including bone marrow lesions, sub-articular bone attrition, synovitis, effusion and innervation of usually insensitive tissues. LINK_TSG6 is a short recombinant peptide comprising the LINK module of human TSG-6.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals

Abstract

This invention relates to the treatment of osteoarthritic pain, or pain associated with osteoarthritis, and particularly for LINK_TSG6 polypeptide for use in the treatment of osteoarthritic pain. Osteoarthritis is caused by the deterioration of cartilage in joints and is characterised by pain and a loss of mobility in the affected joints. Osteoarthritic pain results from multiple factors including bone marrow lesions, sub- articular bone attrition, synovitis, effusion and innervation of usually insensitive tissues. LINK_TSG6 is a short recombinant peptide comprising the LINK module of human TSG-6.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, the methods can involve treatment of a subject with a therapeutic agent that degrades hyaluronan and/or an agent that neutralizes a hyaluronan receptor, e.g., CD44, such as an anti-CD44 antibody.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/728 - Hyaluronic acid
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Monomer(s) based on a 3,4-dihydro-2H-1,3-benzoxazine derivative. Alternatively, a composition comprising a mixture of the monomer(s) and of a second benzoxazine derivative selected from the group consisting of monofunctional amines bridged with diphenolic compounds, monophenolic compounds bridged with diamines and diamines bridged by diphenolic compounds, or a mixture thereof. These compounds are suited for the preparation of benzoxazine derivative heterogeneous polymers, for example having the shape of coatings or films, exhibiting enhanced anti-inflammatory and/or anti-oxidant properties. A material with a coated substrate with the heterogeneous polymer may be a part of implantable materials, such as implantable metallic apparatus such as a catheter, a metallic implant, or a metallic prosthesis, biologically compatible. These implantable materials may be safely used because they are preventing any inflammatory and/or oxidative reaction(s) from a host into which the coated substrate is grafted or implanted.

IPC Classes  ?

• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C08G 73/02 - Polyamines
• C09D 179/04 - Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors
• A61L 27/34 - Macromolecular materials
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 29/08 - Materials for coatings
• A61L 29/16 - Biologically active materials, e.g. therapeutic substances

Abstract

The present invention relates to resist compostions, in particular to photoresists that can be used in photolithography, especially in the fabrication of integrated circuits and derivative products. The resist compositions of the invention include an anti-scattering component which has a significant amount of empty space, and thus fewer scattering centers, such that radiation-scattering events are more limited during exposure. Such anti-scattering effects can lead to improved resolutions by reducing the usual proximity effects associated with lithographic techniques, allowing the production of smaller, higher resolution microchips. Furthermore, certain embodiments involve anti-scattering components which are directly linked to the resist components, which can improve the overall lithographic chemistry to provide benefits both in terms of resolution and resist sensitivity.

IPC Classes  ?

• G03F 7/20 - Exposure; Apparatus therefor
• G03F 7/004 - Photosensitive materials
• G03F 7/031 - Organic compounds not covered by group
• G03F 7/038 - Macromolecular compounds which are rendered insoluble or differentially wettable
• G03F 7/16 - Coating processes; Apparatus therefor
• G03F 7/32 - Liquid compositions therefor, e.g. developers
• H01L 21/027 - Making masks on semiconductor bodies for further photolithographic processing, not provided for in group or
• H01L 21/56 - Encapsulations, e.g. encapsulating layers, coatings
• H01L 21/768 - Applying interconnections to be used for carrying current between separate components within a device
• H01L 21/78 - Manufacture or treatment of devices consisting of a plurality of solid state components or integrated circuits formed in, or on, a common substrate with subsequent division of the substrate into plural individual devices

Abstract

The present invention provides a tissue repair scaffold comprising a knitted body, wherein the knitted body is made of a yarn comprising polycaprolactone (PCL), and the knitted body comprises a plurality of apertures that remain open when the scaffold is stretched under load. The scaffold is particularly adapted for tendon repair. The present invention also relates to a tissue repair device comprising the scaffold, and a method of making the scaffold.

IPC Classes  ?

• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61F 2/08 - Muscles; Tendons; Ligaments
• A61L 27/56 - Porous or cellular materials
• D01D 5/00 - Formation of filaments, threads, or the like
• D04B 1/22 - Weft knitting processes for the production of fabrics or articles not dependent on the use of particular machines; Fabrics or articles defined by such processes specially adapted for knitting goods of particular configuration
• D04B 1/16 - Other fabrics or articles characterised primarily by the use of particular thread materials synthetic threads

Abstract

The present invention relates to a substrate having a surface of variable infrared emissivity, wherein at least one surface of the substrate comprises a plurality of pendent composite sheets fixed thereto. The present invention also relates to methods of varying the infrared emissivity on a surface of a substrate and its uses in dynamic thermal management, camouflage technology infrared communication and as a heat regulating protective cover.

IPC Classes  ?

• C23C 28/00 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and
• C23C 14/00 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
• C23C 16/00 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes
• F41H 3/02 - Covers, e.g. screens, nets
• B32B 3/00 - Layered products essentially comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products essentially having particular features of form
• B32B 5/00 - Layered products characterised by the non-homogeneity or physical structure of a layer
• B32B 7/00 - Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical propert; Layered products characterised by the interconnection of layers
• B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
• B32B 15/00 - Layered products essentially comprising metal
• B32B 27/00 - Layered products essentially comprising synthetic resin
• B32B 37/00 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding

Abstract

It relates to an reduced graphene oxide (rGO) film having a total thickness from 20 nm to 5 micrometer, which comprises a stack of rGO layers comprising flakes, wherein the distance between two consecutive layers is from 0.2 to 0.7 nm, and to an electrically back-contacted conductive reduced graphene oxide (rGO) structure comprising it together with an additional conductive support on which the rGO is deposited. It also relates to a process for the preparation of the rGO film and the electrically back-contacted conductive rGO structure, and to electronic devices for detecting, receiving and/or inducing electrical signals.

IPC Classes  ?

• C01B 32/198 - Graphene oxide

Abstract

A spacecraft, for example a satellite, or a part thereof having a coating comprising a 2D material on an outer surface thereof is described. The 2D material comprises one or more elements, excluding C, N and S, in an amount of at least 50 at.%; and respective oxides of the one or more elements of the 2D material have a vapour pressure of at most 10 Pa at a temperature of 323 K.

IPC Classes  ?

• C09D 5/08 - Anti-corrosive paints
• B01J 19/10 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing sonic or ultrasonic vibrations
• B64G 1/22 - Parts of, or equipment specially adapted for fitting in or to, cosmonautic vehicles
• C09D 5/44 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes for electrophoretic applications
• C09D 7/40 - Additives
• C25D 13/02 - Electrophoretic coating characterised by the process with inorganic material

Abstract

Methods of identifying subjects having complement-related disorders, or at risk of such disorders, are disclosed. Also disclosed are methods for selecting subjects for treatment with complement-targeted therapies, and methods of treatment of subjects with such therapies.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

This invention relates to a method of separating oils and aqueous media. The method uses membranes comprising 2D phyllosilicate coatings. The invention also relates to membranes for use in said methods.

IPC Classes  ?

• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/10 - Supported membranes; Membrane supports
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
• B01D 69/12 - Composite membranes; Ultra-thin membranes
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• B01D 71/02 - Inorganic material
• B01D 71/56 - Polyamides, e.g. polyester-amides

Abstract

Described herein is a membrane for use in membrane distillation, comprising a porous polymer matrix and functionalized graphene or graphene oxide, the graphene or graphene oxide being functionalized with a polyhedral oligomeric silsesquioxane. The present membrane have improved separation performance.

IPC Classes  ?

• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/14 - Dynamic membranes
• B01D 71/34 - Polyvinylidene fluoride
• B01D 71/02 - Inorganic material
• B01D 61/36 - Pervaporation; Membrane distillation; Liquid permeation

Abstract

The present invention relates to methods for simultaneously identifying and/or detecting distinct classes of biomarker in biofluid samples, such as blood.

IPC Classes  ?

• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

The invention relates to methods for capturing, quantifying and analyzing cell free nucleic acid (cfNA) in biofluid samples, such as blood and urine.

IPC Classes  ?

• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

The present invention relates to methods of regulating G protein activity, and related methods for the treatment of therapeutic conditions, for example retinal degeneration, by transforming a cell with a bistable opsin to activate a G protein, and provide a phototransduction response.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C07K 14/46 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates
• A61P 27/02 - Ophthalmic agents
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

Composite materials are described that comprise a polymer, a lignocellulosic compound, a coupling agent and graphene. The lignocellulosic compound is a shive. When compared with materials formed solely from the neat polymer, the composite materials offer improvements in terms of shrinkage properties, tensile and flexural properties and heat distortion properties. Moreover, the material properties of the composite material can be tailored according to the intended application of the material. Also described is a process for preparing the composite materials, as well as various uses of the composite materials.

IPC Classes  ?

• C08L 23/12 - Polypropene
• C08L 97/02 - Lignocellulosic material, e.g. wood, straw or bagasse

Abstract

The present invention relates to electrochemical devices based on zinc-ion chemistries. It uses a carefully formulated water-in-salt gel electrolyte. The present invention also relates to a cathode material ideally suited to use with such an electrolyte.

IPC Classes  ?

• H01M 10/36 - Accumulators not provided for in groups
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 4/583 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/02 - Electrodes composed of, or comprising, active material

Abstract

Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, is described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, treatment of a subject with a therapeutic agent that neutralizes interleukin 13 (IL-13) can result in reduced risk for mechanical ventilation in the subject. Also described are methods of predicting risk of mechanical ventilation in subjects with COVID-19.

IPC Classes  ?

• A61K 38/19 - Cytokines; Lymphokines; Interferons
• A61K 38/20 - Interleukins
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• C12P 21/08 - Monoclonal antibodies

Abstract

An illumination insert for an NMR spectrometer, the illumination insert being shaped to receive a sample and comprising a light guide portion for guiding light from a light source, and a diffuser portion for diffusing light received from the light guide portion towards a sample received in the illumination insert.

IPC Classes  ?

• G01R 33/30 - Sample handling arrangements, e.g. sample cells, spinning mechanisms

Abstract

An illumination insert for an NMR spectrometer, the illumination insert being shaped to receive a sample and comprising a light guide portion for guiding light from a light source, and a diffuser portion for diffusing light received from the light guide portion towards a sample received in the illumination insert.

IPC Classes  ?

• G01R 33/30 - Sample handling arrangements, e.g. sample cells, spinning mechanisms

Abstract

The present invention relates to methods of decontaminating irradiated nuclear graphite. The method comprises immersing the irradiated nuclear graphite in a molten salt electrolyte, and subjecting the irradiated nuclear graphite to an electrochemical treatment.

IPC Classes  ?

• G21F 9/00 - Treating radioactively contaminated material; Decontamination arrangements therefor
• G21F 9/30 - Processing

Abstract

The invention relates to biomarkers. In particular, the invention relates to cancer biomarkers and their use in assessment of cancer likelihood in a subject.

IPC Classes  ?

• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Abstract

This invention relates to devices that can controllably vary the properties of graphene with respect to different wavelengths of electromagnetic radiation and particularly its optical properties. The electronically variable optical surfaces of the invention comprise graphene layers with intercalated metal (e.g. lithium) ions. The cell comprises an Li-NMC anode as ion source, an ionic liquid electrolyte, and an multilayer graphene cathode.

IPC Classes  ?

• G02B 5/00 - Optical elements other than lenses
• G02B 5/20 - Filters
• G02B 5/22 - Absorbing filters
• G02F 1/15 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect

Abstract

The present invention relates to polymer compounds that have antiviral activity. The compounds have the structural Formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to compositions comprising them, and to their use in the prevention or treatment of viral infections.

IPC Classes  ?

• A61P 31/12 - Antivirals
• A01N 25/10 - Macromolecular compounds
• C08F 112/14 - Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing hetero atoms
• C08F 120/38 - Esters containing sulfur

Abstract

Methods for detecting and determining the level of complement proteins are disclosed, in particular using mass spectrometry. Also disclosed are methods of identifying subjects having or at risk of developing a complement-related disorder, and methods of treating the same.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to an improved method of providing photoreceptor function to a cell, for example for use in the treatment of retinal degeneration. The present invention also relates to compositions and kits, in particular for use in such methods.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 38/51 - Lyases (4)
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• C07K 14/72 - Receptors; Cell surface antigens; Cell surface determinants for hormones
• C12N 9/88 - Lyases (4.)
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4409 - Non-condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid

Abstract

The present invention relates to resist compostions, in particular to photoresists that can be used in photolithography, especially in the fabrication of integrated circuits and derivative products. The resist compositions of the invention include an anti-scattering component which has a significant amount of empty space, and thus fewer scattering centers, such that radiation-scattering events are more limited during exposure. Such anti-scattering effects can lead to improved resolutions by reducing the usual proximity effects associated with lithographic techniques, allowing the production of smaller, higher resolution microchips. Furthermore, certain embodiments involve anti-scattering components which are directly linked to the resist components, which can improve the overall lithographic chemistry to provide benefits both in terms of resolution and resist sensitivity.

IPC Classes  ?

• G03F 7/20 - Exposure; Apparatus therefor
• G03F 7/16 - Coating processes; Apparatus therefor
• G03F 7/32 - Liquid compositions therefor, e.g. developers
• G03F 7/038 - Macromolecular compounds which are rendered insoluble or differentially wettable
• G03F 7/031 - Organic compounds not covered by group
• H01L 21/027 - Making masks on semiconductor bodies for further photolithographic processing, not provided for in group or
• H01L 21/768 - Applying interconnections to be used for carrying current between separate components within a device
• H01L 21/78 - Manufacture or treatment of devices consisting of a plurality of solid state components or integrated circuits formed in, or on, a common substrate with subsequent division of the substrate into plural individual devices
• H01L 21/56 - Encapsulations, e.g. encapsulating layers, coatings
• G03F 7/004 - Photosensitive materials
• H05K 3/30 - Assembling printed circuits with electric components, e.g. with resistor
• H01L 23/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details of semiconductor or other solid state devices

Abstract

The present invention relates to methods of assessing whether an individual has Parkinson's Disease (PD) and/or is no longer responding to treatment, the method comprising the identification of one or more volatile compounds in the sebum of the individual. The present invention also relates to methods of extracting and detecting analytes from sebum.

IPC Classes  ?

• H01J 49/26 - Mass spectrometers or separator tubes
• G01N 1/40 - Concentrating samples
• G01N 33/487 - Physical analysis of biological material of liquid biological material